160 related articles for article (PubMed ID: 14675084)
21. Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties.
Haller CA; Cui W; Wen J; Robson SC; Chaikof EL
J Vasc Surg; 2006 Apr; 43(4):816-23. PubMed ID: 16616242
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells.
Marcus AJ; Safier LB; Hajjar KA; Ullman HL; Islam N; Broekman MJ; Eiroa AM
J Clin Invest; 1991 Nov; 88(5):1690-6. PubMed ID: 1939654
[TBL] [Abstract][Full Text] [Related]
23. Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury.
Sashindranath M; Dwyer KM; Dezfouli S; Selan C; Crikis S; Lu B; Yuan Y; Hickey MJ; Peter K; Robson SC; Cowan PJ; Nandurkar HH
Purinergic Signal; 2017 Jun; 13(2):259-265. PubMed ID: 28343356
[TBL] [Abstract][Full Text] [Related]
24. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
[TBL] [Abstract][Full Text] [Related]
25. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism.
Kaneider NC; Egger P; Dunzendorfer S; Noris P; Balduini CL; Gritti D; Ricevuti G; Wiedermann CJ
Arterioscler Thromb Vasc Biol; 2002 Jun; 22(6):894-900. PubMed ID: 12067895
[TBL] [Abstract][Full Text] [Related]
26. Characterization of NTPDase (NTPDase1; ecto-apyrase; ecto-diphosphohydrolase; CD39; EC 3.6.1.5) activity in human lymphocytes.
Leal DB; Streher CA; Neu TN; Bittencourt FP; Leal CA; da Silva JE; Morsch VM; Schetinger MR
Biochim Biophys Acta; 2005 Jan; 1721(1-3):9-15. PubMed ID: 15652174
[TBL] [Abstract][Full Text] [Related]
27. Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection.
Imai M; Takigami K; Guckelberger O; Enjyoji K; Smith RN; Lin Y; Csizmadia E; Sévigny J; Rosenberg RD; Bach FH; Robson SC
Mol Med; 1999 Nov; 5(11):743-52. PubMed ID: 10656876
[TBL] [Abstract][Full Text] [Related]
28. CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation.
Banz Y; Beldi G; Wu Y; Atkinson B; Usheva A; Robson SC
Br J Haematol; 2008 Aug; 142(4):627-37. PubMed ID: 18537971
[TBL] [Abstract][Full Text] [Related]
29. Human solCD39 inhibits injury-induced development of neointimal hyperplasia.
Drosopoulos JH; Kraemer R; Shen H; Upmacis RK; Marcus AJ; Musi E
Thromb Haemost; 2010 Feb; 103(2):426-34. PubMed ID: 20024507
[TBL] [Abstract][Full Text] [Related]
30. Altered E-NTPDase/E-ADA activities and CD39 expression in platelets of sickle cell anemia patients.
Castilhos LG; Doleski PH; Adefegha SA; Becker LV; Ruchel JB; Leal DB
Biomed Pharmacother; 2016 Apr; 79():241-6. PubMed ID: 27044834
[TBL] [Abstract][Full Text] [Related]
31. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions.
Marcus AJ; Safier LB; Broekman MJ; Islam N; Fliessbach JH; Hajjar KA; Kaminski WE; Jendraschak E; Silverstein RL; von Schacky C
Thromb Haemost; 1995 Jul; 74(1):213-7. PubMed ID: 8578460
[TBL] [Abstract][Full Text] [Related]
32. Roles of Asp54 and Asp213 in Ca2+ utilization by soluble human CD39/ecto-nucleotidase.
Drosopoulos JH
Arch Biochem Biophys; 2002 Oct; 406(1):85-95. PubMed ID: 12234494
[TBL] [Abstract][Full Text] [Related]
33. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.
Enjyoji K; Sévigny J; Lin Y; Frenette PS; Christie PD; Esch JS; Imai M; Edelberg JM; Rayburn H; Lech M; Beeler DL; Csizmadia E; Wagner DD; Robson SC; Rosenberg RD
Nat Med; 1999 Sep; 5(9):1010-7. PubMed ID: 10470077
[TBL] [Abstract][Full Text] [Related]
34. Kindlin-2 regulates hemostasis by controlling endothelial cell-surface expression of ADP/AMP catabolic enzymes via a clathrin-dependent mechanism.
Pluskota E; Ma Y; Bledzka KM; Bialkowska K; Soloviev DA; Szpak D; Podrez EA; Fox PL; Hazen SL; Dowling JJ; Ma YQ; Plow EF
Blood; 2013 Oct; 122(14):2491-9. PubMed ID: 23896409
[TBL] [Abstract][Full Text] [Related]
35. Characterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasma.
Jiang ZG; Wu Y; Csizmadia E; Feldbrügge L; Enjyoji K; Tigges J; Toxavidis V; Stephan H; Müller CE; McKnight CJ; Moss A; Robson SC
Purinergic Signal; 2014 Dec; 10(4):611-8. PubMed ID: 25165006
[TBL] [Abstract][Full Text] [Related]
36. Thrombo-Inflammation: A Focus on NTPDase1/CD39.
Morello S; Caiazzo E; Turiello R; Cicala C
Cells; 2021 Aug; 10(9):. PubMed ID: 34571872
[TBL] [Abstract][Full Text] [Related]
37. Transmembrane domains confer different substrate specificities and adenosine diphosphate hydrolysis mechanisms on CD39, CD39L1, and chimeras.
Grinthal A; Guidotti G
Biochemistry; 2002 Feb; 41(6):1947-56. PubMed ID: 11827541
[TBL] [Abstract][Full Text] [Related]
38. Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells.
Imai M; Kaczmarek E; Koziak K; Sévigny J; Goepfert C; Guckelberger O; Csizmadia E; Schulte Am Esch J; Robson SC
Biochemistry; 1999 Oct; 38(41):13473-9. PubMed ID: 10521254
[TBL] [Abstract][Full Text] [Related]
39. Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis.
Zimmermann H
Nat Med; 1999 Sep; 5(9):987-8. PubMed ID: 10470068
[No Abstract] [Full Text] [Related]
40. Overexpression of CD39/nucleoside triphosphate diphosphohydrolase-1 decreases smooth muscle cell proliferation and prevents neointima formation after angioplasty.
Koziak K; Bojakowska M; Robson SC; Bojakowski K; Soin J; Csizmadia E; Religa P; Gaciong Z; Kaczmarek E
J Thromb Haemost; 2008 Jul; 6(7):1191-7. PubMed ID: 18485080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
